185 related articles for article (PubMed ID: 15961986)
1. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Turpeinen M; Tolonen A; Uusitalo J; Jalonen J; Pelkonen O; Laine K
Clin Pharmacol Ther; 2005 Jun; 77(6):553-9. PubMed ID: 15961986
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.
Palovaara S; Pelkonen O; Uusitalo J; Lundgren S; Laine K
Clin Pharmacol Ther; 2003 Oct; 74(4):326-33. PubMed ID: 14534519
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
Loboz KK; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht JK; Zanger UM; McLachlan AJ
Clin Pharmacol Ther; 2006 Jul; 80(1):75-84. PubMed ID: 16815319
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
Kharasch ED; Mitchell D; Coles R
J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
[TBL] [Abstract][Full Text] [Related]
5. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation.
Fan L; Wang JC; Jiang F; Tan ZR; Chen Y; Li Q; Zhang W; Wang G; Lei HP; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Apr; 65(4):403-9. PubMed ID: 19066872
[TBL] [Abstract][Full Text] [Related]
6. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.
Nishiya Y; Hagihara K; Ito T; Tajima M; Miura S; Kurihara A; Farid NA; Ikeda T
Drug Metab Dispos; 2009 Mar; 37(3):589-93. PubMed ID: 19047469
[TBL] [Abstract][Full Text] [Related]
8. Drug interaction study between bupropion and ticlopidine in male CF-1 mice.
Molnari JC; Hassan HE; Moeller BM; Myers AL
Biol Pharm Bull; 2011; 34(3):447-51. PubMed ID: 21372402
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
[TBL] [Abstract][Full Text] [Related]
10. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.
Farid NA; Payne CD; Ernest CS; Li YG; Winters KJ; Salazar DE; Small DS
J Clin Pharmacol; 2008 Jan; 48(1):53-9. PubMed ID: 18094219
[TBL] [Abstract][Full Text] [Related]
11. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.
Qin WJ; Zhang W; Liu ZQ; Chen XP; Tan ZR; Hu DL; Wang D; Fan L; Zhou HH
Br J Clin Pharmacol; 2012 Dec; 74(6):999-1004. PubMed ID: 22519658
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
Lau AJ; Chang TK
Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
[TBL] [Abstract][Full Text] [Related]
14. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
Peltoniemi MA; Saari TI; Hagelberg NM; Reponen P; Turpeinen M; Laine K; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2011 Aug; 90(2):296-302. PubMed ID: 21716267
[TBL] [Abstract][Full Text] [Related]
15. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
[TBL] [Abstract][Full Text] [Related]
17. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects.
Kim H; Bae SK; Park SJ; Shim EJ; Kim HS; Shon JH; Liu KH; Shin JG
Br J Clin Pharmacol; 2010 Jul; 70(1):126-31. PubMed ID: 20642555
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
Kharasch ED; Lenze EJ
Drug Metab Dispos; 2024 Apr; 52(5):455-466. PubMed ID: 38467432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]